Table 3.
Age- and multivariate-adjusted HRs for the association between confirmed psoriasis and non-fatal CVD
| Cases * | Person- years |
Age-adjusted HR (95% CI) |
Multivariate-adjusted HR † (95% CI) |
|
|---|---|---|---|---|
| Non-fatal CVD | ||||
| No psoriasis | 694 | 1,690,318 | 1.00 | 1.00 |
| psoriasis | 19 | 18,750 | 2.41 (1.53-3.80) | 2.06 (1.31-3.26) |
| Non-fatal MI | ||||
| No psoriasis | 346 | 1,690,650 | 1.00 | 1.00 |
| psoriasis | 13 | 18,758 | 3.28 (1.88-5.70) | 2.63 (1.51-4.59) |
| Non-fatal Stroke | ||||
| No psoriasis | 351 | 1,690,645 | 1.00 | 1.00 |
| psoriasis | 7 | 18,763 | 1.77 (0.84-3.73) | 1.61 (0.76-3.42) |
Four Non-fatal MI cases occurred in participants diagnosed with non-fatal stroke.
Simultaneously adjusted for age, body mass index (underweight <18.5, normal weight 18.5-24.9, overweight 25-29.9, and obesity ≥40 kg/m2), smoking status (never, past, current smoking with 1-14, 15-24 or ≥25 cigarettes/day), alcohol intake (no, <5.0, 5.0-9.9 or ≥10.0 g/d), physical activity (<3.0, 3.0-8.9, 9.0-17.9, 18.0-26.9 or ≥27.0 metabolic equivalent hours/wk), race (Caucasian, Asian, Hispanic or African American), family history of stroke/MI (yes or no), hypertension (yes or no), hypercholesterolemia (yes or no), current aspirin use (yes or no), multi-vitamin use (yes or no), postmenopausal hormone use (premenopause, never, current or past users) , oral contraceptives use (never, past or current users).